PACIRA BIOSCIENCES, INC. Payments to Acquire Short-term Investments
PACIRA BIOSCIENCES, INC. (PCRX) reported Payments to Acquire Short-term Investments of $3.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $3.90M, a 22.77% decline year-over-year.
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $27.59M, a 38.95% decline year-over-year.
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $38.77M, a 61.71% decline year-over-year.
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for fiscal 2025 was $141.04M, a 44.08% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for fiscal 2024 was $252.21M, a 83.28% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for fiscal 2023 was $137.61M, a 64.51% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. payments to acquire short-term investments for fiscal 2022 was $387.69M, a 36.60% decline from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month | Payments to Acquire Short-term Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.90M 10-Q · filed 2026-08-04 | $31.50M derived: sum of 3 quarters · filed 2026-08-04 | $70.26M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $27.59M derived: sum of 2 quarters · filed 2026-04-30 | $66.36M derived: sum of 3 quarters · filed 2026-04-30 | $71.41M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $27.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $66.36M derived: sum of 2 quarters · filed 2026-02-26 | $71.41M derived: sum of 3 quarters · filed 2026-08-04 | $141.04M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $38.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $43.82M derived: sum of 2 quarters · filed 2026-08-04 | $113.45M 10-Q · filed 2025-11-06 | $158.65M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $74.69M 10-Q · filed 2026-08-04 | $119.88M derived: sum of 3 quarters · filed 2026-08-04 | $221.12M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $69.63M 10-Q · filed 2026-04-30 | $114.82M derived: sum of 2 quarters · filed 2026-04-30 | $216.06M derived: sum of 3 quarters · filed 2026-04-30 | $265.79M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $45.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $146.43M derived: sum of 2 quarters · filed 2026-02-26 | $196.16M derived: sum of 3 quarters · filed 2026-02-26 | $252.21M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $101.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $150.96M derived: sum of 2 quarters · filed 2025-11-06 | $207.02M 10-Q · filed 2025-11-06 | $232.94M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $49.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $105.78M 10-Q · filed 2025-08-05 | $131.71M derived: sum of 3 quarters · filed 2026-02-26 | $173.88M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $56.05M 10-Q · filed 2025-05-08 | $81.98M derived: sum of 2 quarters · filed 2026-02-26 | $124.15M derived: sum of 3 quarters · filed 2026-02-26 | $144.17M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $25.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $68.10M derived: sum of 2 quarters · filed 2026-02-26 | $88.11M derived: sum of 3 quarters · filed 2026-02-26 | $137.61M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $42.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $62.19M derived: sum of 2 quarters · filed 2024-11-06 | $111.68M 10-Q · filed 2024-11-06 | $179.94M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $20.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $69.51M 10-Q · filed 2024-07-30 | $137.77M derived: sum of 3 quarters · filed 2025-02-27 | $269.55M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $49.50M 10-Q · filed 2024-05-07 | $117.76M derived: sum of 2 quarters · filed 2025-02-27 | $249.54M derived: sum of 3 quarters · filed 2025-02-27 | $281.58M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $68.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $200.04M derived: sum of 2 quarters · filed 2025-02-27 | $232.08M derived: sum of 3 quarters · filed 2025-02-27 | $387.69M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $131.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $163.82M derived: sum of 2 quarters · filed 2023-11-02 | $319.43M 10-Q · filed 2023-11-02 | $417.42M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $32.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $187.64M 10-Q · filed 2023-08-02 | $285.64M derived: sum of 3 quarters · filed 2024-02-29 | $481.00M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $155.60M 10-Q · filed 2023-05-03 | $253.60M derived: sum of 2 quarters · filed 2024-02-29 | $448.96M derived: sum of 3 quarters · filed 2024-02-29 | $580.44M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $98.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $293.36M derived: sum of 2 quarters · filed 2024-02-29 | $424.83M derived: sum of 3 quarters · filed 2024-02-29 | $611.49M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $195.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $326.84M derived: sum of 2 quarters · filed 2022-11-03 | $513.49M 10-Q · filed 2022-11-03 | $733.34M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $131.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $318.13M 10-Q · filed 2022-08-03 | $537.98M derived: sum of 3 quarters · filed 2023-02-28 | $792.38M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $186.65M 10-Q · filed 2022-05-04 | $406.50M derived: sum of 2 quarters · filed 2023-02-28 | $660.91M derived: sum of 3 quarters · filed 2023-02-28 | $660.56M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $219.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $474.25M derived: sum of 2 quarters · filed 2023-02-28 | $473.91M derived: sum of 3 quarters · filed 2023-02-28 | $546.52M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $254.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $254.05M derived: sum of 2 quarters · filed 2021-11-03 | $326.66M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $72.26M 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | $72.61M 10-Q · filed 2021-05-04 | ||||
| 2019-09-30 | $78.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $197.40M derived: sum of 2 quarters · filed 2020-10-30 | $220.09M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $119.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $141.96M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $22.69M 10-Q · filed 2020-05-07 | ||||
| 2018-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $52.17M derived: sum of 2 quarters · filed 2019-11-08 | $182.75M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $52.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $182.75M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $130.58M 10-Q · filed 2019-05-02 | ||||
| 2017-09-30 | $161.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $255.68M derived: sum of 2 quarters · filed 2018-11-01 | $436.02M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $94.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $274.79M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | $180.34M 10-Q · filed 2018-05-03 | ||||
| 2016-09-30 | $36.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $90.55M derived: sum of 2 quarters · filed 2017-11-08 | $158.39M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $53.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $121.79M 10-Q · filed 2017-08-02 | |||
| 2016-03-31 | $67.84M 10-Q · filed 2017-05-04 | ||||
| 2015-09-30 | $32.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $75.26M derived: sum of 2 quarters · filed 2016-11-02 | $125.20M 10-Q · filed 2016-11-02 | $124.63M derived: sum of 4 quarters · filed 2016-11-02 | |
| 2015-06-30 | $42.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $92.92M 10-Q · filed 2016-08-04 | $92.35M derived: sum of 3 quarters · filed 2016-08-04 | $179.77M derived: sum of 4 quarters · filed 2016-08-04 | |
| 2015-03-31 | $49.94M 10-Q · filed 2016-05-02 | $49.37M derived: sum of 2 quarters · filed 2016-05-02 | $136.78M derived: sum of 3 quarters · filed 2016-05-02 | $170.83M derived: sum of 4 quarters · filed 2016-05-02 | |
| 2014-12-31 | -$570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $86.85M derived: sum of 2 quarters · filed 2015-10-27 | $120.89M derived: sum of 3 quarters · filed 2015-10-27 | $139.84M 10-K · filed 2015-02-24 | |
| 2014-09-30 | $87.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $121.46M derived: sum of 2 quarters · filed 2015-10-27 | $140.41M 10-Q · filed 2015-10-27 | $152.59M derived: sum of 4 quarters · filed 2015-10-27 | |
| 2014-06-30 | $34.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $52.99M 10-Q · filed 2015-07-30 | $65.18M derived: sum of 3 quarters · filed 2015-07-30 | $80.07M derived: sum of 4 quarters · filed 2015-07-30 | |
| 2014-03-31 | $18.95M 10-Q · filed 2015-04-30 | $31.13M derived: sum of 2 quarters · filed 2015-04-30 | $46.02M derived: sum of 3 quarters · filed 2015-04-30 | $61.46M derived: sum of 4 quarters · filed 2015-04-30 | |
| 2013-12-31 | $12.19M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $27.08M derived: sum of 2 quarters · filed 2015-02-24 | $42.51M derived: sum of 3 quarters · filed 2015-02-24 | $114.30M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $14.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $30.33M derived: sum of 2 quarters · filed 2014-10-30 | $102.11M 10-Q · filed 2014-10-30 | $102.00M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-06-30 | $15.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $87.22M 10-Q · filed 2014-07-31 | $87.11M derived: sum of 3 quarters · filed 2015-02-24 | $88.50M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-03-31 | $71.78M 10-Q · filed 2014-05-01 | $71.68M derived: sum of 2 quarters · filed 2015-02-24 | $73.06M derived: sum of 3 quarters · filed 2015-02-24 | ||
| 2012-12-31 | -$109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $1.27M derived: sum of 2 quarters · filed 2015-02-24 | $54.05M 10-K · filed 2015-02-24 | ||
| 2012-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $54.16M 10-Q · filed 2013-10-31 | |||
| 2012-06-30 | $52.77M 10-Q · filed 2013-08-06 | ||||
| 2011-12-31 | $31.95M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $32.86M derived: sum of 2 quarters · filed 2014-02-25 | $52.62M 10-K · filed 2014-02-25 | $29.97M 10-K · filed 2012-03-27 | |
| 2011-09-30 | $916.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $20.67M 10-Q · filed 2011-10-31 | |||
| 2011-06-30 | $19.75M 10-Q · filed 2011-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |